KRAS and non-small cell lung carcinoma: Moreover, simultaneous RASSF1A methylation and KRAS mutation shortened survival in patients with NSCLC [141], suggesting that RASSF1A methylation may synergically promote the growth of lung cancer with KRAS mutation by inhibiting the Hippo pathway, which needs further confirmation.